Nevro Q1 2020 Earnings Report
Key Takeaways
Nevro Corp. reported a 6% increase in worldwide revenue for Q1 2020, reaching $87.5 million, despite a negative impact from COVID-19 related cancellations. U.S. revenue increased by 14%, while international revenue decreased by 26%. The company's net loss from operations improved by 45% compared to the prior year period.
Worldwide revenue increased by 6% to $87.5 million, despite COVID-19 impacts.
U.S. revenue increased by 14% to $75.3 million, with trial growth at 7% and permanent implant growth at 12%.
International revenue decreased by 26% to $12.2 million due to COVID-19 restrictions.
Net loss from operations improved by 45% to $23.1 million.
Nevro
Nevro
Forward Guidance
Due to the rapidly evolving environment and continued uncertainties resulting from the impact of COVID-19, Nevro withdrew its previously announced annual guidance for 2020 on April 1, 2020. Due to the uncertain scope and duration of the pandemic, and the timing of global economic recovery, the Company cannot, at this time, reliably estimate the future impact on its operations and financial results.